
|Articles|September 14, 2015
- Squamous NSCLC
- Volume 1
- Issue 1
Evolving Paradigms in Squamous NSCLC: Conclusion
Author(s)Staff Writer
Squamous cell lung cancer represents a distinct molecular pathologic NSCLC with unmet therapeutic needs, especially after failure of first-line platinum-based doublet chemotherapy.
Advertisement
This article is Part III of a series. View parts I and II:Evolving Paradigms in Squamous NSCLC> >
Articles in this issue
about 10 years ago
Cancer Immunotherapy: Evolving Treatment Options in Squamous NSCLCabout 10 years ago
Evolving Paradigms in Squamous NSCLC: Referencesover 10 years ago
Evolving Paradigms in Squamous NSCLC: IntroductionAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5







































